Newsletter Tool

Featured Story

UnitedHealthcare adopts limited coverage policy for Aduhelm

By Paige Minemyer

The health insurance giant's coverage policy aligns with Medicare's recent coverage determination, with the insurer saying it will cover the drug for people in clinical trials and will require prior authorization.

Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe

By Zoey Becker

After Amarin lost U.S. patent protections for its sole drug Vascepa, the company embarked on cost cuts and shifted to a digital-first marketing strategy. Now, the company aims to "stabilize" U.S. sales and grow its presence in Europe, execs said Wednesday.

FDA clears Abbott test to spot four STIs at once amid soaring case rates

By Andrea Park

The test was cleared by the FDA for samples collected in a healthcare setting, but Abbott also aims to bring STI screening into the home.

All Takeda wants for its billion-dollar gene therapy spending spree is functional cures

By Annalee Armstrong

Madhu Natarajan, head of Takeda’s Rare Disease Drug Discovery unit, knows that to many, cure is a “four-letter word.” But that's no reason not to try.

IllumiCare launches EHR tool to automate clinical trial referral at point of care

By Anastassia Gliadkovskaya

The app, which claims to be the first of its kind, suggests to providers in real-time if a patient meets the referral criteria for a clinical trial.

Regeneron counts on Eylea's track record to fend off Roche rival Vabysmo

By Kevin Dunleavy

As Regeneron's Eylea tries to fend of competition from Roche's longer-acting Vabysmo, the company will rely on the track record of its blockbuster which raked in $9.2 billion in revenue last year. Regeneron’s answer is its own high-dose version—now in phase 3 testing—could reach the market in late 2023.

PM Tracker

Featured Story

UnitedHealthcare adopts limited coverage policy for Aduhelm

Top Stories

Bancel has 'never been as busy' amid M&A talks as Moderna preps for life after COVID

Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe

FDA clears Abbott test to spot four STIs at once amid soaring case rates

All Takeda wants for its billion-dollar gene therapy spending spree is functional cures

IllumiCare launches EHR tool to automate clinical trial referral at point of care

Fresenius Medical Care taps former Philips exec to take the reins after CEO's retirement

Regeneron counts on Eylea's track record to fend off Roche rival Vabysmo

FDA approves Orthofix's ultrasonic bone fracture healing system

Biogen shoves Aduhelm to the side. It's time for lecanemab

Siemens nearly doubles diagnostics forecast for the year amid renewed COVID testing surge

Highmark Ventures, GuideWell back Healthmap's $35M round to scale up kidney care